United States of America — [18 September, 2025] – According to the latest research report by The Insight Partners, the Vascular Closure Device Market is projected to grow from US$ 1.73 billion in 2022 to US$ 3.03 billion by 2030, registering a CAGR of 7.1% during 2022–2030. The growth is fueled by the rising prevalence of cardiovascular diseases and the growing demand for minimally invasive procedures, while risks of infection linked to these devices remain a restraint.

Market Analysis

Vascular closure devices (VCDs) are used after cardiovascular procedures requiring catheterization to achieve rapid and reliable hemostasis. They are increasingly replacing traditional manual compression methods, reducing patient discomfort, hospital stay, and recovery time. The surge in cardiovascular diseases (CVDs) such as acute myocardial infarction, atherosclerosis, and angina pectoris, combined with the preference for minimally invasive surgeries, is a major driver for the market.

Market Drivers & Opportunities

• Higher Demand for Minimally Invasive Devices: Advancements in medical technology and the shift toward less invasive procedures have accelerated the adoption of VCDs.
• Emerging Economies: Developing nations such as India, China, Brazil, and South Africa offer significant growth opportunities, driven by improving healthcare infrastructure, rising awareness, and an expanding aging population.

Key Market Segmentation

• By Product Type: Active Approximators, Passive Approximators, External Hemostatic Devices
• By Access: Femoral Access, Radial Access
• By Procedure: Interventional Cardiology, Interventional Radiology, Endovascular Surgery
• By End User: Hospitals, Ambulatory Surgical Centers, Others

Regional Insights

• North America leads the global vascular closure device market, driven by technological advancements, new product approvals, and increasing cardiovascular procedures.
• Asia-Pacific is anticipated to witness the fastest growth due to rising healthcare expenditure, expanding hospital networks, and growing CVD prevalence.

Recent Developments

• May 2022: Teleflex Inc. received Health Canada approval for its MANTA Vascular Closure Device, the first biomechanical closure system designed for large bore femoral access.
• March 2023: Haemonetics Corporation invested ~US$ 31.72 million in Vivasure Medical to expand vascular closure innovations.

Key Players

Major companies shaping the market include Abbott Laboratories, Medtronic Plc, Haemonetics Corp., Becton Dickinson and Co., Cardinal Health Inc., Cordis Corp., Transluminal Technologies LLC, Vasorum Ltd, and ENDOCOR GmbH & Co. KG.

Report Scope:

• Market Size (2022): US$ 1.73 Billion
• Market Size (2030): US$ 3.03 Billion
• CAGR (2022–2030): 7.1%
• Forecast Period: 2022–2030
• Regions Covered: North America, Europe, Asia-Pacific, Middle East & Africa, South & Central America

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:
If you have any queries about this report or if you would like further information, please get in touch with us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch